Don’t want emails from us anymore? Click here to unsubscribe.

A major meat processing firm’s stock is surging after posting strong earnings, a logistics company just reported solid growth, and a tiny biotech stock is skyrocketing 175% after FDA approval for its first-in-human trial. Read on to know all about it.

Disaster Recovery Play (Sponsored)

Could This Stock Be the Biggest Winner in Disaster Recovery?

Wildfires and hurricanes have left devastation in their wake—but one company is turning the chaos into a booming business.

With a $15M-$35M recovery contract in hand, this small-cap stock is processing high-value scrap metal critical for rebuilding efforts. A new shredder has doubled processing capacity, adding millions in revenue, while rising tariffs are fueling demand for domestic recycled metals.

Insiders are loading up on shares, and with the stock trading at just $0.42, the window for early investors won’t stay open for long.

Get the full details before the market catches on.

Futures 📈

What to Watch

Earnings:

Economic Reports:

Veterinary Diagnostics

Idexx Labs’ Q4 Results Better Than Expected; Plans Canine Cancer Test Launch in March

Idexx Laboratories [IDXX] reported fourth-quarter earnings that exceeded analyst forecasts on both revenue and profit today. The veterinary diagnostics and technology firm’s net income of $216.1 million, or $2.62 per share, is up from $194.5 million, or $2.32 per share, in the same quarter last year. Excluding one-time charges, adjusted earnings are at $2.53 per share, surpassing Wall Street estimates of $2.40.

Revenue climbed to $954.3 million in the quarter, marking an increase from $901.6 million in the prior year and beating the anticipated $935.1 million. CEO Jay Mazelsky highlighted the company’s ongoing expansion and announced plans to introduce a canine lymphoma cancer screening test in the U.S. and Canada by late March.

Looking ahead, Idexx provided revenue guidance for 2025 in the range of $4.06 billion to $4.17 billion, aligning with analysts’ expectations of $4.14 billion. The company also projects full-year earnings per share between $11.74 and $12.24, slightly above the forecasted $11.94 per share.

With solid financial performance and a growing portfolio of veterinary diagnostics, Idexx remains well-positioned for continued growth in the coming year. Investors are closely watching its upcoming product launches and expansion strategies in the animal healthcare market.

Food Processing

Tyson Foods Reports Strong Q1 Results and Stock Surges

Tyson Foods’ [TSN] first-quarter earnings are above analyst expectations, with both earnings per share (EPS) and revenue coming in higher than forecasts. The company’s non-GAAP EPS of $1.14 is higher than estimates by $0.26. Revenue is at $13.62 billion, reflecting a 2.3% year-over-year increase and beating projections by $160 million.

The firm’s stock is up 4.3% in premarket trade.

For fiscal 2025, Tyson expects adjusted operating income between $1.9 billion and $2.3 billion. Revenue is projected to remain flat or increase by up to 1% compared to 2024. The company has allocated between $1.0 billion and $1.2 billion for capital expenditures, focusing on profit improvement initiatives and essential maintenance projects.

Tyson anticipates net interest expenses of approximately $375 million for the year, while liquidity is expected to remain above the $1.0 billion minimum target, with a current total of $4.5 billion as of December 28, 2024. Free cash flow is forecasted to range between $1.0 billion and $1.6 billion. The company also projects an adjusted effective tax rate of around 25% for the fiscal year.

With a strong start to 2025 and a steady financial outlook, Tyson remains focused on strategic investments and operational efficiencies to maintain profitability in a competitive market.

Breakout Cyber Stock (Sponsored)

A Cybersecurity Stock to Watch in 2025

With cyber threats reaching new highs, Fortune 500 companies like ING, Boeing, and Visa are securing their data with a NASDAQ-listed cybersecurity leader.

This company is rapidly expanding in a trillion-dollar industry, locking in major contracts and positioning itself for significant growth.

(By clicking the link above, you agree to receive emails from Huge Alerts. You can opt out at any time. - Privacy Policy)

On February 4th, a major cybersecurity alert will reveal full details on this stock—one that could be primed for a breakout.

Early investors could get in before the market catches on.

Click here to get the details before the February 4th reveal.

(By clicking the link above, you agree to receive emails from Huge Alerts. You can opt out at any time. - Privacy Policy)

Logistics

Saia Reports Strong Q4 Sales Growth, Expects Solid 2025 Performance

Saia’s [SAIA] fourth-quarter results are better than expected, causing its shares to go up by 1% in early trading. The freight transportation company’s revenue of $789 million, reflecting a 5% year-over-year increase, is higher than analyst estimates of $777.3 million.

Earnings per share (EPS) is at $2.84, slightly above the projected $2.77 but down from $3.33 in the same quarter last year. The company’s operating margin is 12.9%, a drop from 15% a year ago due to higher expenses.

CEO Fritz Holzgrefe highlighted the company’s expansion efforts, noting that Saia opened 21 new terminals and relocated nine others during 2024, bringing its total to 214 across the U.S. The company also onboarded 1,300 new employees, reinforcing its commitment to service growth.

Looking ahead, analysts anticipate revenue growth of 8.5% over the next year, driven by continued demand in the freight transportation sector. Saia’s full-year earnings per share are expected to reach $13.51, representing a 14.2% increase.

HCW Biologics Inc. [HCWB] - Last Close: $0.28

HCW Biologics Inc. is a clinical-stage biopharmaceutical firm focused on innovative immunotherapies that tackle chronic inflammation to extend health span.

Its stock is up nearly 175% in premarket trading because the U.S. FDA has just cleared the company's Investigational NDA, which will let HCW Biologics initiate a first-in-human Phase 1 clinical trial for its drug HCW9302 in patients.

GH Research PLC [GHRS] - Last Close: $10.60

GH Research PLC is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological disorders.

The Phase 2b clinical trial for its lead candidate GH001 for TRD has just met both primary and secondary endpoints, which is causing this stock to skyrocket nearly 90% in premarket trade.

Triumph Group, Inc. [TGI] - Last Close: $18.74

Triumph Group, Inc., is a leading aerospace supplier of mission-critical engineered systems and proprietary components.

TGI’s shares are up more than 30% in premarket trading after announcing that it is being acquired by PE firms Warburg Pincus and Berkshire Partners in an all-cash transaction valued at approximately $3 billion, representing a premium of ~123% over the company's unaffected closing stock price.

Spotting Hidden Opportunities (Sponsored)

The Next Big Stock Could Be Hiding in Plain Sight

Apple, Microsoft, Netflix—at one point, they were just names buried in a stock ticker, ignored by most investors.

But a few saw the potential early. A few got in before the breakout.

These stock alerts are built for that exact moment—spotting high-potential stocks before they explode onto everyone’s radar.

(By clicking the link above, you agree to receive emails from GuyStocks. You can opt out at any time. - Privacy Policy)

And the best part? It’s 100% free. No gimmicks. No fluff. Just real market alerts, delivered straight to your inbox.

Click here to get your first alert now.

(By clicking the link above, you agree to receive emails from GuyStocks. You can opt out at any time. - Privacy Policy)

Everything Else

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club